Menu Search
Equities

Lumos Diagnostics Holdings Ltd

LDXHF:PKC

Lumos Diagnostics Holdings Ltd

Actions
  • Price (USD)0.0291
  • Today's Change0.00 / 0.00%
  • Shares traded100.00k
  • 1 Year change-56.24%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024 20:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Company’s products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.

  • Revenue in AUD (TTM)12.56m
  • Net income in AUD-13.49m
  • Incorporated2018
  • Employees--
  • Location
    Lumos Diagnostics Holdings Ltd100 Albert Rd, Level 4SOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 39087-1598
  • Websitehttps://lumosdiagnostics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.